Understanding the differences between these two therapies is essential for anyone considering peptide-based weight management
Oral Semaglutide Demonstrates meaningful but generally smaller weight-loss effects Shows strong improvements in blood sugar control (HbA1c), particularly in diabetic populations Requires higher daily doses to compensate for lower absorption However, some studies point to similar outcomes in the short term
Weight Loss: At 36 weeks, weight reductions were dose-dependent: 3.19% (0.5 mg), 7.9210.37% (4 mg), 16.3416.81% (8 mg), and 16.94% (12 mg), compared to 3.0% for placebo and 2.02% for dulaglutide
This provides the medium-term view of glucose control that spot fasting glucose measurements can miss
Potential impurities in drug substances: compound-specific toxicology limits for 20 synthetic reagents and by-products, and a class-specific toxicology limit for alkyl bromides